Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Dasanu
Constantin A
CA
Reale
Michael A
MA
Bauer
Frank
F
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003131:Combined Modality Therapy; D019938:Cyclin D1 / Q000502:physiology; D003907:Dexamethasone / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects; D000077269:Lenalidomide; D020522:Lymphoma, Mantle-Cell / Q000473:pathology*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D009363:Neoplasm Proteins / Q000502:physiology; D016609:Neoplasms, Second Primary / Q000473:pathology*; D011719:Pyrazines / Q000008:administration & dosage; D000069283:Rituximab; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014182:Transplantation, Autologous / Q000009:adverse effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; C530104:CCND1 protein, human; D009363:Neoplasm Proteins; D011719:Pyrazines; D019938:Cyclin D1; D000069283:Rituximab; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan